Defining the risks of mesenchymal stromal cell therapy.
Abstract We address the issue of the potential for malignant transformation of cultured mesenchymal stromal cells (MSC) commonly used in clinical cell-therapy protocols and describe the culture conditions under which tumorigenesis is likely to be an extremely uncommon event.
Prockop
Darwin J
DJ
Texas A&M Health Science College of Medicine, Institute for Regenerative Medicine at Scott & White, Temple, TX 76502, USA. Prockop@medicine.tamhsc.edu
Brenner
Malcolm
M
Fibbe
Willem E
WE
Horwitz
Edwin
E
Le Blanc
Katarina
K
Phinney
Donald G
DG
Simmons
Paul J
PJ
Sensebe
Luc
L
Keating
Armand
A
D053687:Adult Stem Cells / Q000378:metabolism* / Q000473:pathology; D000818:Animals; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism; D018929:Cell Culture Techniques; D049109:Cell Proliferation; D002471:Cell Transformation, Neoplastic; D016922:Cellular Senescence; D002986:Clinical Trials as Topic; D006801:Humans; D045164:Mesenchymal Stem Cell Transplantation / Q000009:adverse effects*; D059630:Mesenchymal Stem Cells / Q000378:metabolism* / Q000473:pathology; D051379:Mice; D012307:Risk Factors; D017154:Stromal Cells / Q000378:metabolism* / Q000473:pathology / Q000637:transplantation; D019098:Telomerase / Q000235:genetics / Q000378:metabolism
D014408:Biomarkers, Tumor; D019098:Telomerase